Table 1

Patient characteristics

Parameters	Total (n=37)		Arm 1 (n=20)		Arm 2 (n=17)		p-value
Parameters	No.	%	No.	%	No.	%	p-value
Age, years							0.67
Median	75		75		74
Range	53–86		53–86		55–84
Race: white	4	10.80	2	10.00	2	11.80	0.94
Disease location							0.55
Bone only	19	51.40	9	45	10	58.80
Soft tissue only	5	13.50	2	10	3	17.60
Bone and soft tissue	11	29.70	7	35	4	23.50
Visceral	2	5.40	2	10	0
Number of bone mets							0.51
0	7	18.90	3	15	4	23.50
1-10	17	45.90	11	55	6	35.30
>10	13	35.10	6	30	7	41.20
ECOG performance status							0.57
0	27	73	14	70	13	76.50
1	9	24.3	6	30	3	17.60
2	1	2.70	0		1	5.90
Median PSA, ng/mL Range	21.9 0.33–636.8		20.2 2.1–636.8		26.3 0.33–529		0.71
Median alkaline phosphatase, U/L Range	76 41–741		68.5 41–321		92 46–741		0.28
Median hemoglobin, g/dL Range	13 9.8–15.3		12.9 10.2–15.3		13 9.8–14.9		0.98
Median LDH, U/L Range	181 114–677		180 114–677		181 130–229		0.32
Gleason Score							1
≤7	17	45.90	9	45	8	47.10
≥8	15	40.50	8	40	7	41.20
Unknown	5	13.50	3	15	2	11.80
Patients with prior chemotherapy for mCRPC	7	18.90	3	15	4	23.50	0.68
Patients receiving docetaxel-based chemotherapy subsequent to study treatment	11	29.70	6	30	5	29.40	1
Patients with two or more previous anti-androgen therapies	23	62.20	14	70	9	52.90	0.33